Anavex Life Sciences Management
Management Kriterienprüfungen 2/4
Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.
Wichtige Informationen
Terrie Kellmeyer
Geschäftsführender
n/a
Gesamtvergütung
| Prozentsatz des Geschäftsführergehalts | n/a |
| Amtszeit als Geschäftsführer | no data |
| Eigentum des Geschäftsführers | n/a |
| Durchschnittliche Amtszeit des Managements | 2.6yrs |
| Durchschnittliche Amtszeit der Vorstandsmitglieder | 11.2yrs |
Jüngste Management Updates
Recent updates
Neues Narrativ • Mar 05
Long-Term Neurology Pipeline And Precision Medicine Work Will Support A Stronger Outlook
Catalysts About Anavex Life Sciences Anavex Life Sciences is a clinical stage biopharmaceutical company focused on oral precision medicine therapies for neurological disorders such as early Alzheimer's disease, schizophrenia related conditions, Parkinson's disease, Fragile X syndrome and Rett syndrome. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Feb 10
Anavex: Negative EU Opinion Leaves Blarcamesine In Regulatory Purgatory
Summary Anavex Life Sciences faces regulatory setbacks after the EMA adopted a negative opinion of blarcamesine in Alzheimer's, citing efficacy, safety, and trial design concerns. AVXL's pipeline progress is stalled, with no ongoing clinical trials beyond Compassionate Use and scant details on future development timelines. Financially, the company holds $131.7 million in cash and minimal expenses, providing a multi-year runway but limited near-term catalysts. Given the lack of progress and regulatory limbo, I upgrade AVXL from 'Strong Sell' to 'Sell' as valuation has declined substantially. Read the full article on Seeking AlphaAnalyseartikel • May 21
We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Feb 14
Anavex: Looking At Different Statistical Approaches Before EMA Opinion
Summary Anavex Life Sciences Corp.'s stock surged over 50% due to EMA's acceptance of blarcamesine for Alzheimer's review, marking a pivotal moment for the company. Despite mixed trial results, blarcamesine showed significant cognitive improvements, meeting key endpoints, though it failed in functional assessments. Financially, Anavex has a market cap of $720M and a cash runway of 8–10 quarters, with ongoing R&D expenses. Given the EMA review's potential impact, I am considering a small investment, though not right now, acknowledging AVXL stock's high volatility and associated risks. Read the full article on Seeking AlphaSeeking Alpha • Jan 10
The Misconceptions About Anavex Life Sciences' Blarcamesine Phase 2b/3 Trial In Alzheimer's Disease
Summary Anavex Life Sciences' lead drug, Blarcamesine, failed to meet one of the two co-primary endpoints in its phase 2b/3 Alzheimer's trial, casting doubt on its efficacy and approval prospects. The trial's data inconsistencies, significant toxicity, and methodological flaws undermine the drug's potential for regulatory approval by the EMA. Despite a large market potential, the likelihood of approval is low, therefore we argue Anavex's fair valuation is cash basis ($1–$2 per share). Anavex's current financials show it is well-funded, but without successful trials, its future remains bleak. Read the full article on Seeking AlphaAnalyseartikel • Dec 25
We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • Dec 24
Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis
Summary Anavex Life Sciences remains one of the few non-amyloid Alzheimer's drug developers, with a market cap just under $1bn and stock up 90% YTD. Other biotech firms in the AD space like Cassava, Annovis, and Alector have faced significant setbacks, including failed trials and financial struggles. Despite my previous “Sell” rating, Anavex stock has shown resilience, up over 350% in five years, and 90% year-to-date, contrasting with peers' declining fortunes. Biogen and Lilly's approved amyloid-targeting drugs have limited efficacy and safety risks, highlighting the need for alternative Alzheimer's treatments like Anavex's approach. Unfortunately, I see too many red flags waving to endorse AVXL, but time will tell — the European approval shot is a major catalyst upcoming that I am bearish on. Read the full article on Seeking AlphaSeeking Alpha • Dec 08
Anavex: EU Approval Application Is A Precipitous Moment
Summary Anavex (AVXL) has submitted an MAA for blarcamesine in Alzheimer's, a critical step that puts their molecule under regulatory scrutiny. Despite past trial failures, Anavex's Phase 2b/3 trial showed significant cognitive improvements, though it failed one co-primary endpoint. Data inconsistencies and lack of US clinical trials raise concerns, but EU approval could still be possible. The EMA's decision on blarcamesine, expected by mid-2025, will be crucial, especially given the FDA's controversial approval of Biogen's Aduhelm. Read the full article on Seeking AlphaSeeking Alpha • Nov 11
Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease
Summary Panax ginseng shows the highest effectiveness in treating Alzheimer's because it inhibits nitro-oxidative stress, scavenges peroxynitrite, and reverses part of its damage, leading to sustained cognitive improvements over two years. Anavex's Blarcamesine may slow mild Alzheimer's progression due to its antioxidant capacity, with results from a 96-week trial potentially aiding regulatory approval. Cassava Sciences' Simufilam's effectiveness is limited to one year for mild Alzheimer's, with no residual effects after discontinuation, and mixed results in combined mild and moderate groups. Safety profiles differ, with simufilam being safer but less effective long-term compared to blarcamesine. The latter may cause confusion and dizziness. Read the full article on Seeking AlphaSeeking Alpha • Nov 05
Anavex: Understanding Their Latest Alzheimer's Data News With Caution
Summary On Thursday, Oct. 31, Anavex announced new data from their phase 2b/3 Alzheimer's trial, which was presented at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 conference. This news sent the stock soaring, with an ~16% increase in price. I take a look at the new data and share my thoughts here. Read the full article on Seeking AlphaSeeking Alpha • Oct 08
Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)
Summary Anavex's lead drug, ANAVEX2-73, failed its Phase 2/3 trial for Rett syndrome, and Alzheimer's data showed questionable efficacy and concerning safety issues. The company's financial health is stable with a cash runway of about four years, but operational risks and rising costs are significant concerns. AVXL's decision to seek EU approval for ANAVEX2-73 based on limited data is perplexing, especially given the stringent regulatory environment. The overall recommendation is a "strong sell" due to poor clinical results, overvaluation, and high operational and financial risks. Read the full article on Seeking AlphaSeeking Alpha • Jul 29
Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising
Summary Anavex Life Sciences shared latest data from its SIGMAR-protein targeting drug Blarcamesine yesterday, in Alzheimer's Disease. On a positive note, data showed clinical decline was slowed by 38.5% in the 50-mg arm, and 34.6% in the 30mg arm. On the negative side, the secondary endpoint was not met, and there was a seemingly high number of study withdrawals. Anavex wants to file for approval of Blarcamesine in Europe this year, and also with the FDA in the US. My suspicion is that the FDA will insist on further studies, and EMA may not be convinced on efficacy and safety. Read the full article on Seeking AlphaAnalyseartikel • Jul 17
Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analyseartikel • Apr 01
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analyseartikel • Sep 19
Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Geschäftsführer
Terrie Kellmeyer
no data
Amtszeit
Dr. Terrie Kellmeyer, Ph.D. served as Senior Vice President of Regulatory Affairs of Aardvark Therapeutics, Inc. since May 2025 until 2026. She served as Senior Vice President of Clinical Development at An...
Führungsteam
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Principal Financial Officer & Treasurer | 10.6yrs | US$555.27k | 0.025% $ 62.2k | |
| Interim Chief Executive Officer | no data | keine Daten | keine Daten | |
| VP of Corporate | no data | keine Daten | keine Daten | |
| Senior Vice President of Nonclinical Development | 5yrs | keine Daten | keine Daten | |
| Vice President & Head of Biostatistics | 3.2yrs | keine Daten | keine Daten | |
| Senior VP & Head of Research and Development | 2yrs | keine Daten | keine Daten | |
| Senior VP & Global Head of Neurology | less than a year | keine Daten | keine Daten |
2.6yrs
Durchschnittliche Betriebszugehörigkeit
Erfahrenes Management: AVXLDas Führungsteam des Unternehmens gilt als erfahren (2.6 Jahre durchschnittliche Betriebszugehörigkeit).
Vorstandsmitglieder
| Name | Position | Amtszeit | Vergütung | Eigentümerschaft |
|---|---|---|---|---|
| Independent Chairman | 5yrs | US$364.06k | 0% $ 0 | |
| Member of the Scientific Advisory Board | 11.2yrs | keine Daten | keine Daten | |
| Member of the Scientific Advisory Board | 15.3yrs | keine Daten | keine Daten | |
| Member of the Scientific Advisory Board | 12.4yrs | keine Daten | keine Daten | |
| Member of Scientific Advisory Board | 7.5yrs | keine Daten | keine Daten | |
| Member of the Scientific Advisory Board | 12.5yrs | keine Daten | keine Daten | |
| Member of the Scientific Advisory Board | no data | keine Daten | keine Daten | |
| Member of the Scientific Advisory Board | 12yrs | keine Daten | keine Daten | |
| Member of the Scientific Advisory Board | 11.2yrs | keine Daten | keine Daten | |
| Member of the Scientific Advisory Board | 9.5yrs | keine Daten | keine Daten | |
| Independent Director | 9.3yrs | US$348.06k | 0.0054% $ 13.6k | |
| Lead Independent Director | 8.2yrs | US$364.06k | 0% $ 0 |
11.2yrs
Durchschnittliche Betriebszugehörigkeit
59yo
Durchschnittliches Alter
Erfahrener Vorstand: AVXLDie Vorstandsmitglieder sind sehr erfahren ( 11.2 ).
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/05/22 07:01 |
| Aktienkurs zum Tagesende | 2026/05/22 00:00 |
| Gewinne | 2025/12/31 |
| Jährliche Einnahmen | 2025/09/30 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Anavex Life Sciences Corp. wird von 9 Analysten beobachtet. 2 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Caroline Palomeque | Berenberg |
| Yun Zhong | Brean Capital Historical (Janney Montgomery) |
| Jason Kolbert | D. Boral Capital LLC. |